Clinical Trials · NCT00035256

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Name: Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Teriparatide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 330
Start date: Oct 2001
Locations: 5 sites, United States, Canada
Primary endpoint: The study is designed to compare the effect of 1 year of raloxifene treatment with the effect of placebo on maintaining teriparatide-induced increases in spine and hip BMD.

View Teriparatide compound reference